Combination therapyPhase 3 trialInvestigational
Pembrolizumab + Lenvatinib
How it works
Combination of pembrolizumab, which blocks PD-1, and lenvatinib, which blocks VEGF, to enhance the immune system's ability to attack cancer cells and inhibit angiogenesis.
Cancer types
Melanoma— All patients
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median progression-free survival of approximately 7 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.